Revalia Bio provides a platform for Human Data Trials, integrating human tissue data to accelerate preclinical drug discovery. This infrastructure delivers high-fidelity, organ-based insights to biopharma leaders, enabling earlier target validation and de-risking clinical development. The service aims to reduce R&D waste by providing clinically relevant human data before costly trials commence.
Funding
$12.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many chronic organ-centered diseases lack effective treatments, leading to poor patient outcomes and a significant unmet medical need. Current therapeutic approaches often fail to address the underlying causes of these conditions, resulting in limited efficacy and potential side effects.
Solution
Revalia Bio is developing curative drugs for chronic organ-centered diseases by leveraging insights gained from organ donation. The company aims to transform the therapeutic landscape by identifying novel targets and developing advanced biopharmaceutical techniques to address the root causes of these diseases. By understanding the biological processes involved in organ health and disease, Revalia Bio seeks to create targeted therapies that can restore organ function and improve patient outcomes.
Target Audience
The primary target audience includes patients suffering from chronic organ-centered diseases and the healthcare professionals who treat them.
Features
- Focus on identifying novel drug targets based on organ donation insights.
- Development of advanced biopharmaceutical techniques for targeted drug delivery.
- Emphasis on addressing the underlying causes of chronic organ-centered diseases.
- Aim to restore organ function and improve patient outcomes.